Canton Strategic Holdings, Inc. CNTN PHARMA
Company Overview
Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States. It operates in two segments, Digital Asset Treasury and Clinical Stage Bio-technology. The company is involved in the operation of Canton Coin-centric digital asset treasury strategies, including validator operations and network participation; application support and strategic investments; collaboration and ecosystem advancement; capital raising and treasury expansion; token management - locking, lending, and options; Canton Foundation; and governance and risk management. It also researches and develops GV104, a buccal film formulation of nalmefene for the treatment of respiratory depression and prophylactic protection against synthetic opioid exposure in military and first responders; and GV023, an oral anti-tumor necrosis factor-alpha monoclonal antibody that addresses critical limitation of IV gold standard for the treatment of repeated intravenous infusions. The company was formerly known as Tharimmune, Inc. and changed its name to Canton Strategic Holdings, Inc. in February 2026. Canton Strategic Holdings, Inc. was incorporated in 2017 and is headquartered in Red Bank, New Jersey.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +68.94% |
| 6 Months: | -49.89% |
| 3 Months: | -15.85% |
| 1 Month: | +19.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)52.23 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 71.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CNTN Canton Strategic Holdings, Inc. PHARMA | 2.23 | -14.87 | $177.69M | 0.00% | -3.90% | -42.21% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -1.47M | -1.10M | -541.11K | -1.35M | -1.64M | -2.13M | -2.71M | -2.36M | -1.85M | -2.35M | -2.37M | -3.87M | -2.55M | -1.85M | -2.09M | -36.87M |
| Net Income | -2.25M | -1.56M | -853.44K | -2.94M | -1.64M | -2.13M | -2.69M | -2.34M | -1.82M | -2.26M | -2.33M | -3.80M | -2.54M | -1.86M | -2.10M | -47.34M |
| Diluted EPS | - | - | - | - | 0.14 | -0.18 | -5.84 | -52.06 | -39.42 | -2.55 | -2.42 | -2.45 | -0.99 | -0.64 | -0.34 | -0.23 |
| R&D Expense | 895.91K | 674.76K | 313.13K | 307.83K | 455.55K | 831.84K | 1.05M | 1.03M | 488.18K | 1.03M | 999.55K | 2.28M | 594.07K | 546.20K | 277.80K | 267.82K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -1.81M | -3.21M | -6.88M | -9.46M | -12.43M | -20.11M |
| Net Income | -2.42M | -2.21M | -8.47M | -9.32M | -12.20M | -35.92M |
| Diluted EPS | - | - | -18.72 | -107.02 | -9.41 | -1.12 |
| R&D Expense | 847.27K | 1.84M | 2.28M | 3.56M | 6.39M | 3.07M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 294.80K | 621.68K | 6.69M | 10.95M | 3.72M | 519.15M |
| Total Equity | -1.62M | -3.72M | -4.68M | 5.54M | 9.13M | 1.31M | 397.93M |
| Cash & Equivalents | - | - | - | 6.51M | 10.94M | - | - |
| Total Liabilities | - | 4.01M | 5.31M | 1.14M | 1.82M | 2.41M | 121.22M |
| Current Liabilities | - | 2.73M | 4.53M | 1.14M | 1.82M | 2.41M | 3.29M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.08M | -1.09M | -6.56M | -7.30M | -10.90M | -16.13M |
| Investing Cash Flow | - | - | - | - | - | -77.57M |
| Financing Cash Flow | 1.23M | 898.75K | 13.06M | 11.72M | 3.53M | 107.17M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 65.0% | 47.1% | -152.8% | -102.1% | -932.8% | -9.0% |
| ROCE % | 74.4% | 82.0% | -124.1% | -103.5% | -950.9% | -3.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | ARK Investment Management, LLC | 4.59% | 3.66M | $8.41M |
| 2 | Blackrock Inc. | 4.57% | 3.64M | $8.38M |
| 3 | Vanguard Capital Management LLC | 3.79% | 3.02M | $6.94M |
| 4 | DRW Securities, LLC | 2.16% | 1.72M | $3.97M |
| 5 | Geode Capital Management, LLC | 1.78% | 1.42M | $3.27M |
| 6 | State Street Corporation | 1.17% | 929.47K | $2.14M |
| 7 | Sumitomo Mitsui Trust Group, Inc. | 0.88% | 703.36K | $1.62M |
| 8 | Amova Asset Management Americas Inc | 0.88% | 703.36K | $1.62M |
| 9 | Bienville Capital Management, LLC | 0.82% | 650.41K | $1.50M |
| 10 | Vanguard Fiduciary Trust Co | 0.53% | 421.75K | $970.01K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CNTN
We're Not Very Worried About Canton Strategic Holdings' (NASDAQ:CNTN) Cash Burn Rate - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPcUdHM0ZRdzN1U0VoUDA1UnRuOUxwWi1RdG5JeXNqY3A4b3JwQW5yUFY1T29hcHVOcG05clBzbXVtSWNUZV9vc2xnNkUwaUJBeG55OG95YlhsMFJaUmhqU0lFV1RmXzNhRF9QUTFqVjI3N0RZbzBjUm5JbkpOb0pXYXBhMHBBT3Fwc19KN1…
CNTN Should I Buy - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE1nZDVCSU1YMml4T1Q1elFZZFByNG9ta3N6ZWNNclZvLXZsM19TbXozMjVDRzRqbl9panJJZG4zVkoxOGFGUkY3TG1iWEtWdGhLRnBWY2FWMVh2b2J3ZkE?oc=5" target="_blank">CNTN Should I Buy</a> <font c…
$CNTN stock is down 11% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOa1UySVNFZmdDak0zQ0M2TkFnQ3RkREpHZjcxWVB0RFlDTnh3aUFDUmFOTjRlYjI3UV9qcGZHVnFGUmpYbThzU1NoMUF6SEJTY2l3WnhleXBjS1FDRTZvY2ZxNEdMcmtQVnRwRG5ZTTd1aDBqXzZ4UmhyNTMwSzJTZG1aU3hkbmhTM2JWcD…
CNTN Stock Price and Chart — NASDAQ:CNTN - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTFBDZ3JZc2V4WXdsdDZ3YmJqeU5XV0Jmd2dlbllTZ3VsOENQNGI4bU52dGljVWJ6RHVWUHlGaS1LdTNmbXJsYWR6MS0wTkwtSEZZZ2h6eU9LT25pQ2NU?oc=5" target="_blank">CNTN Stock Price and Chart — NASDAQ:CNTN</a…
Canton Strategic Holdings (CNTN) Stock Price, News & Analysis - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTE44Z1ZXSV9sS2lnVHFzVmNBeDluaWxERHhRR0RHUlRBbWF4X0xFc2JLdVM4WGdrRU52NmwwV1duUVdBZ1RGaEZQRi1CVEh3a21fVWxz?oc=5" target="_blank">Canton Strategic Holdings (CNTN) Stock Price, News & An…
Canton Strategic: Highly Intriguing Blockchain Treasury With Tangible Risks (NASDAQ:CNTN) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQei1IMXNMbVd4Y0ltZ21DT3J4d0k1ekZhOHNrUFdHUHNyVzF4V0xpVEJqaVBUQy11MENYeGUyaDUtenZENGV1WDk1c3hMQkR1WDVIbG4tckhCeFJvaHFVVlB1OEdrM0Q2SGxxRlpNaFJaVjFaNnlNMWM1UWxON3FfR3dVYUNaRmtGTVhtd1…
CNTN — Frequently Asked Questions
What is the current share price of Canton Strategic Holdings, Inc. (CNTN)?
As of 2026-09-19 21:16 PDT, Canton Strategic Holdings, Inc. (CNTN) trades at $2.23 on NasdaqCM. Its 52-week range is $1.17 to $7.71.
What is the market capitalisation of CNTN?
Canton Strategic Holdings, Inc. (CNTN) has a market capitalisation of $177.69M on NasdaqCM.
What is the P/E ratio of CNTN?
CNTN trades at a trailing price-to-earnings (P/E) ratio of -14.87. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.38.
What is the return on equity (ROE) of CNTN?
CNTN has a return on equity (ROE) of -42.21%. Its return on capital employed (ROCE) is -3.90%.
Is CNTN a good stock to buy?
This page provides a data-driven analysis of Canton Strategic Holdings, Inc. (CNTN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.